… The goal of this article was to assess the cost-effectiveness of dabigatran versus rivaroxaban
for the prevention of stroke and systemic embolism in Chinese patients with AF from the …

… The objective of this analysis was to evaluate the cost-effectiveness of rivaroxaban compared
with current SOC (enoxaparin overlapped with warfarin) for the treatment of acute deep …

… For stroke or systemic embolism, we used the total number of … Cost-effectiveness of
dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial …

… In this systematic review, we aim to explore studies comparing the cost-effectiveness of
DOACs in the treatment and prevention of VTE. The objective of this systematic review is to …

… : Dabigatran and rivaroxaban have been approved by the US FDA to reduce the risk of stroke
and systemic embolism … , the manufacturer of Pradaxa (dabigatran etexilate) provided the …

… Amongst this group, the sub-group of patients with an ischemic or hemorrhagic stroke,
transient ischemic attack, systemic embolism was extracted. Patients with a former admission for …

… for other registered indications of dabigatran in the Netherlands (ie prevention of VTE in …
total knee replacement surgery, and prevention of stroke and systemic embolism in non-valvular …

… prevention, treatment, and secondary prevention of venous thromboembolic disease. The
clinical results and headline cost-effectiveness … detail on the cost-effectiveness analysis. We …

… AF is the main cause of stroke and systematic embolism (SSE) which can lead to death, … to
estimate the cost-effectiveness dabigatran etexilate versus warfarin for prevention of stroke in …

… The incremental cost-effectiveness ratios of dabigatran 150 and 110 mg, rivaroxaban 20
and 15 mg, apixaban 5 mg, and edoxaban 60 mg versus warfarin were $6,415, $4,225, $4,115 …